GlaxoSmithKline: gets EU approval for HIV two-drug regimen
(CercleFinance.com) - GSK's ViiV Healthcare has received European Union marketing authorisation for its once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection, the British pharmaceutical company said on Wednesday.
The drugmaker announced that the European Commission has granted marketing authorisation for Dovato for the treatment of HIV-1 infection in adults and teenagers weighing at least 40 kg.
This treatment enables patients to take a two-drug regimen in a single pill, while for many years the standard of care for HIV has been a three-drug regimen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The drugmaker announced that the European Commission has granted marketing authorisation for Dovato for the treatment of HIV-1 infection in adults and teenagers weighing at least 40 kg.
This treatment enables patients to take a two-drug regimen in a single pill, while for many years the standard of care for HIV has been a three-drug regimen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.